Bloviation vs. Reality on Stimulus Health-Care Provision

Network News

X Profile
View More Activity
By Steven Pearlstein
Friday, February 13, 2009

To most Americans, the language on Page 52 of the report of the House Committee on Appropriations would have seemed perfectly sensible.

The report spelled out the committee's rationale for including $1.1 billion for something called "comparative effectiveness research" in the massive economic stimulus bill. For those of not steeped in the argot of health policy, that's research done by doctors and statisticians who troll through large number of patient records to determine, for any particular disease, which treatments work best.

"By knowing what works best and presenting this information more broadly to patients and healthcare professionals, those [treatments] that are most effective . . . will be utilized, while those that are found to be less effective and in some cases more expensive will no longer be prescribed."

There's nothing particularly new about comparative effectiveness research -- the National Institutes of Health, along with the Agency for Healthcare Research and Quality, have been doing it for years, with a budget last year of about $335 million. But with the strong backing of the Obama administration, House Democrats are anxious to ramp up the effort, which nearly all experts agree is a necessary first step to reforming a broken health-care system.

To some, however, the wording in last month's House report was anything but innocuous. To them, it was a warning shot across the bow, the camel's nose under the tent of a government-run health system, the dangerous first step on the slippery slope toward European-style health-care rationing.

" 'Stimulus' bill may change health care forever," blared the headline in the Washington Times over a commentary written by Amy Menefee, communications director for the Galen Institute, a nonprofit think tank that aims to bring free-market ideas to the health-care debate.

"Ruin Your Health With the Obama Stimulus Plan," warned Betsy McCaughey, former lieutenant governor of New York and adjunct senior fellow at the conservative Hudson Institute, in a commentary distributed by Bloomberg News several days later.

No sooner had the McCaughey commentary hit the tape then -- what a coincidence! -- radio bloviator Rush Limbaugh was quoting it on his syndicated show, warning that under the world envisioned by the Obama stimulus bill, old people would be denied all costly medical treatments under a new "duty to die" regime meant to save taxpayer money. The McCaughey commentary also got a prominent mention by uber-blogger Matt Drudge.

The next day, the Wall Street Journal's senior economics writer, Stephen Moore, was on Fox News warning that the stimulus bill would put the government in control of what medical treatments you and your family would be allowed to receive. That set the stage for Megyn Kelly's interview with Sen. Arlen Specter, who was virtually browbeat by the anchor until he promised that "we are not going to let the federal government monitor what doctors do."

The Journal's editorial page picked up the campaign the next day, drawing the line of causation from electronic health records -- another beneficiary of the stimulus bill -- to comparative health records to government price controls and then a government-run "health tech monopoly."

This right-wing brushfire didn't start on its own, of course. It was a work of political arson by the country's drugmakers and medical device makers, which have the most to lose if there is solid research showing that some of their most expensive and high-margin products aren't really better than the low-priced spread. The flames were also fanned by "disease groups" like Easter Seals and the American Cancer Society, which fear that any attempt to determine what works best will inevitably lead to a one-size-fits-all approach to treating people with serious chronic conditions.

It's not that these various groups have no reason for concern. If comparative effectiveness research is done badly, or if the results are used simply as an excuse to deny insurance coverage for all expensive treatments, then there would be plenty of reason to get out the pitchforks and storm Capitol Hill. And there are surely examples from Britain and other countries of people being denied access to the latest drugs and procedures, including some that are significantly more effective than other treatments.


CONTINUED     1        >

© 2009 The Washington Post Company

Network News

X My Profile
View More Activity